Why Abzena?
Our focused approach.
In a recent Synlett Letter, Abzena chemists partner with colleagues at Regeneron to report the first scalable, enantioselective route to an Fmoc-protected form of the rare branched amino acid (2 S,3 R)-3,4-dimethyl-2-(methylamino)pentanoic acid.
The first enantioselective synthesis of the Fmoc-protected rare amino acid, 3,4-dimethyl-2-(methylamino)pentanoic acid, is disclosed. The synthesis utilized the chiral oxazolidinone to introduce the first chiral center (>95:5 ee), and then swapped the auxiliary to Ellman’s N-sulfinylimine for setting up the chiral α-amino group (95:5 dr). The newly formed chiral centers were confirmed by X-ray crystallography. With this unique amino acid on hand, naturally occurring macrocyclic peptides will become synthetically accessible.